jeudi 27 octobre 2016

Onco Actu du 27 octobre 2016

3.1 Tabac

Exclusive: India's tobacco industry, government face off ahead of WHO conference [Reuters]

3.3 Prévention - Vaccins

Gardasil leads the charge as Merck vaccines soar in Q3 [FiercePharma]

4.2 Dép., diag. & prono. - Génome

23andMe Has Abandoned The Genetic Testing Tech Its Competition Is Banking On [BuzzFeed]

5.2 Pharma

Myriad's BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib [Myriad]

Lynparza Phase III SOLO-2 trial shows significant progression-free survival benefit [AstraZeneca]

AstraZeneca celebrates a PhIII PARP success for Lynparza, putting pressure on Tesaro rival [EndPoints]

AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy [The Street]

5.2.2 Pharma - Fusions & Acquisitions

Novartis Looks at Up to $5 Billion Deals in Cancer, Generics [Bloomberg]

5.4 Traitements - Economie

Off-Label Drug Coverage in Oncology [ESMO]

6. Lutte contre les cancers

The plight of young scientists [Nature]

6.1 Observation

Cancer survivors take more psych meds than other people [Reuters]

6.11 Patients

Why is it so hard for patients with metastatic cancer to participate in clinical trials? [Philly]

6.8 Communication

New Online Tool Offers Essential Tools for Cancer Survivors [ACS]

Increasing Awareness of Breast Cancer Health Disparities [AACR]